NCT02736474 is a Phase 4 clinical trial of Naltrexone in Obese, sponsored by Shanghai Mental Health Center.

Who is sponsoring NCT02736474?

NCT02736474 is sponsored by Shanghai Mental Health Center.

What drugs are being tested in NCT02736474?

Interventions in NCT02736474: Naltrexone, Placebo Naltrexone, Bupropion, Placebo Bupropion.

What condition does NCT02736474 study?

NCT02736474 studies Obese, Cigarette-smoking, Schizophrenia.

Is NCT02736474 still recruiting?

NCT02736474 is currently completed. Last updated 25 September 2021.

Are results published for NCT02736474?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-09-25 · How we verify

NCT02736474

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Naltrexone and Bupropion Combination on Weight Loss and Smoking Cessation in Obese, Cigarette-smoking Patients With Schizophrenia

Completed Phase 4 Results posted Last updated 25 September 2021

What this trial tests

Phase 4 trial testing Naltrexone in Obese in 22 participants. Completed in 1 July 2018.

Timeline

1 May 2016

Primary endpoint
1 July 2018

1 July 2018

Quick facts

Lead sponsor	Shanghai Mental Health Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	22
Start date	1 May 2016
Primary completion	1 July 2018
Estimated completion	1 July 2018

Drugs / interventions tested

Naltrexone — full drug profile →
Placebo Naltrexone
Bupropion (bupropion) — full drug profile →
Placebo Bupropion

Conditions studied

Obese — all drugs for Obese →
Cigarette-smoking — all drugs for Cigarette-smoking →
Schizophrenia — all drugs for Schizophrenia →

Sponsor

Shanghai Mental Health Center — full company profile →

Who can join

Adults 18 to 65, any sex, with Obese or Cigarette-smoking. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change From Baseline in Weight at 24 Weeks
Time frame: baseline and 24 weeks
evaluate all participants' weight ，weight in kilograms

Sponsor's own description

The purpose of this research is to observe the efficacy of Naltrexone and Bupropion combination on weight loss and smoking cessation from baseline to week 24 compare to placebo.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Antidepressants for smoking cessation.
Howes S, Hartmann-Boyce J, Livingstone-Banks J, Hong B, et al · · 2020 · cited 66× · PMID 32319681 · DOI 10.1002/14651858.cd000031.pub5
Antidepressants for smoking cessation.
Hajizadeh A, Howes S, Theodoulou A, Klemperer E, et al · · 2023 · cited 38× · PMID 37230961 · DOI 10.1002/14651858.cd000031.pub6
Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia.
Lyu X, Du J, Zhan G, Wu Y, et al · · 2018 · cited 20× · PMID 29563871 · DOI 10.3389/fphar.2018.00181

Verify or expand the search:

Other trials of Naltrexone

Trials testing the same drug.

NCT07433413 — Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder · Phase 3 · not yet recruiting
NCT06622239 — Trial to Evaluate the Effects of Naltrexone in Nonsuicidal Self-injury · Phase 2 · not yet recruiting
NCT06426303 — Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Di · Phase 4 · recruiting
NCT05968690 — Naltrexone and Propranolol Combined With Immunotherapy · Phase 1 · recruiting
NCT05458609 — Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep · Phase 3 · completed

Other recruiting trials for Obese

Currently open trials in the same condition.

NCT07411560 — A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in Peopl · Phase 1 · recruiting
NCT06719466 — Diet Intervention on Obesity Related Complication · NA · active not recruiting
NCT06590584 — Validity and Reliability of the 6-minute Pegboard Ring Test in Obese Individuals · recruiting
NCT06562660 — The Effect of Mask Combined With High Flow Oxygen on Preoxygenation During Induction of General Anesthesia in Obese Pati · NA · recruiting
NCT05819853 — Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome · Phase 3 · recruiting

Other Shanghai Mental Health Center trials

Trials by the same sponsor.

NCT07480408 — Neural Mechanisms of the Sensorymotor Circuit in Sensory Phenomena in OCD · NA · not yet recruiting
NCT07479771 — tTIS Targeted of the Striatum as an Intervention for MUD Patients · NA · not yet recruiting
NCT07472673 — Transcranial Temporal Interference Stimulation Targeted of the Amygdala as an Intervention for Alcohol Use Disorder Pati · NA · not yet recruiting
NCT07484750 — Efficacy and Influencing Factors of Mindfulness-Based Exposure Group Therapy for OCD · NA · recruiting
NCT07311655 — Validation of the Accuracy of an AI-Based System for Diagnosing Anxiety Disorders · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02736474 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Mental Health Center
Last refreshed: 25 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02736474.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing